What is DICE Therapeutics, Inc. (DICE)?

DICE Therapeutics, Inc. (DICE) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of DICE?

The current price of DICE is $47.55. Prices are updated in real time on Stocks360.

What is DICE's price-to-earnings (PE) ratio?

DICE's trailing twelve-month PE ratio is -22.97, based on current price and earnings per share data available on Stocks360.

What is DICE's market capitalization?

DICE's market capitalization is $2,270,792,950.00, placing it in the mid-cap tier.

DICE Therapeutics, Inc. (DICE)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$47.55

Market Cap

$2.27B

PE (TTM)

-22.97

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.00

Day Range

$47.46 – $47.83

52-wk Range

$15.08 – $47.90

Avg Volume

N/A

Volume

4.33M

DICE Therapeutics, Inc. (DICE) is a publicly traded company in the Healthcare sector. Latest price: $47.55. Market cap $2.27B. Trailing PE -22.97. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Aug 8, 2023

EPS $-0.74 vs est. $-0.65

Missed by $0.09

Proprietary Signals

Signal snapshot temporarily unavailable.

About DICE Therapeutics, Inc.

DICE Therapeutics, Inc. is a biopharmaceutical firm focused on creating innovative oral drug candidates to address chronic immunological disorders and other medical conditions. The company leverages its proprietary DELSCAPE platform, engineered to identify highly selective oral small molecules that can modulate protein-protein interactions (PPIs) with efficacy comparable to conventional systemic biologics. Their flagship therapeutic asset is DC-806, an orally administered antagonist designed to inhibit interleukin-17, a pivotal pro-inflammatory signaling molecule widely recognized as a validated target across numerous immunology indications. Furthermore, DICE is advancing other oral treatment options, including therapies aimed at the α4β7 integrin for the management of inflammatory bowel diseases, and compounds targeting the αVβ1/αVβ6 integrin to treat idiopathic pulmonary fibrosis. Beyond these areas, the company also dedicates efforts to immuno-oncology, specifically developing antibody-based therapeutics. Established in 2013, DICE Therapeutics is headquartered in South San Francisco, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-22.97×
P/S (TTM)	0.00×
P/B	-9.99×
P/FCF (TTM)	-34.12×
EV / EBITDA	-22.56×
EV / Sales	0.00×
Earnings Yield	-4.36%
Free Cash Flow Yield	-2.93%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.82B
Net Income (TTM)	-$98.98M
Free Cash Flow (TTM)	-$65.90M
Net Debt	-$448.13M
Working Capital	$562.61M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	56.07%
Return on Invested Capital	-14.80%